NEW YORK (AP) — Drugs that treat Type 2 diabetes, HIV and arthritis are among 15 new medications chosen for a Medicare drug price negotiation program that allows the federal government to haggle directly with drug manufacturers, the Trump administration said Tuesday. The government already has negotiated prices for 25 prescription drugs covered by Medicare, including the massively popular GLP-1 weight-loss and diabetes drugs Ozempic, Rybelsus and Wegovy. Retail prescription drugs covered under Medicare Part D are also eligible, as they were in past years. CMS in November announced negotiated drug prices for 15 drugs that would go into effect in 2027. Reduced prices for the first 10 drugs negotiated by the Biden administration in 2024 went into effect at the start of this year.